Evaluation of Caspofungin Susceptibility Testing by the New Vitek 2 AST-YS06 Yeast Card Using a Unique Collection ofFKSWild-Type and Hot Spot Mutant Isolates, Including the Five Most Common Candida Species

Recurrent Episodes of Candidemia Due to Candida glabrata with a Mutation in Hot Spot 1 of theFKS2Gene Developed after Prolonged Therapy with Caspofungin

(2012) María Teresa Durán-Valle et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

DifferentialIn VivoActivities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and withoutFKSResistance Mutations

(2012) Maiken Cavling Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST)*

(2012) Maiken C. Arendrup et al.   CLINICAL MICROBIOLOGY AND INFECTION

Frequency of Decreased Susceptibility and Resistance to Echinocandins among Fluconazole-Resistant Bloodstream Isolates of Candida glabrata

(2012) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Evaluation of CLSI M44-A2 Disk Diffusion and Associated Breakpoint Testing of Caspofungin and Micafungin Using a Well-Characterized Panel of Wild-Type andfksHot Spot Mutant Candida Isolates

(2011) Maiken Cavling Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Disseminated Candidiasis Caused by Candida albicans with Amino Acid Substitutions in Fks1 at Position Ser645 Cannot Be Successfully Treated with Micafungin

(2011) J. L. Slater et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Echinocandin Susceptibility Testing ofCandidaspp. Using EUCAST EDef 7.1 and CLSI M27-A3 Standard Procedures: Analysis of the Influence of Bovine Serum Albumin Supplementation, Storage Time, and Drug Lots

(2011) Maiken Cavling Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

EUCAST technical note on anidulafungin

(2011) M.C. Arendrup et al.   CLINICAL MICROBIOLOGY AND INFECTION

Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria

(2011) M.A. Pfaller et al.   DRUG RESISTANCE UPDATES

Multicenter Comparison of the Vitek 2 Antifungal Susceptibility Test with the CLSI Broth Microdilution Reference Method for Testing Caspofungin, Micafungin, and Posaconazole against Candida spp.

(2011) J. F. Peterson et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Echinocandin Susceptibility Testing of Candida Isolates Collected during a 1-Year Period in Sweden

(2011) Marlene Axner-Elings et al.   JOURNAL OF CLINICAL MICROBIOLOGY

FKS2Mutations Associated with Decreased Echinocandin Susceptibility ofCandida glabratafollowing Anidulafungin Therapy

(2010) Sofia Costa-de-Oliveira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Novel FKS Mutations Associated with Echinocandin Resistance in Candida Species

(2010) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity

(2010) K. Niimi et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Breakthrough Invasive Candidiasis in Patients on Micafungin

(2010) C. D. Pfeiffer et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest Methods with the CLSI Broth Microdilution Method for Echinocandin Susceptibility Testing of Candida Species

(2010) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Use of Epidemiological Cutoff Values To Examine 9-Year Trends in Susceptibility of Candida Species to Anidulafungin, Caspofungin, and Micafungin

(2010) M. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Echinocandin Susceptibility Testing of Candida Species: Comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, Disk Diffusion, and Agar Dilution Methods with RPMI and IsoSensitest Media

(2009) M. C. Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3- -D-Glucan Synthase: Implication for the Existing Susceptibility Breakpoint

(2009) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mutations in the fks1 Gene in Candida albicans, C. tropicalis, and C. krusei Correlate with Elevated Caspofungin MICs Uncovered in AM3 Medium Using the Method of the European Committee on Antibiotic Susceptibility Testing

(2008) M. Desnos-Ollivier et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Reduced Candida glabrata Susceptibility Secondary to an FKS1 Mutation Developed during Candidemia Treatment

(2008) J. D. Cleary et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Naturally Occurring Proline-to-Alanine Amino Acid Change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis Accounts for Reduced Echinocandin Susceptibility

(2008) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans: Implications for Interpretive Breakpoints

(2008) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts

(2008) J.L. Rodriguez-Tudela et al.   CLINICAL MICROBIOLOGY AND INFECTION